Irinotecan Bendalis

Irinotecan, the active ingredient in Irinotecan Bendalis, is a topoisomerase I inhibitor presented as a sterile injectable solution for intravenous use. It treats metastatic colorectal cancer in adult patients. GNH USA supplies Irinotecan Bendalis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Irinotecan is a topoisomerase I inhibitor used primarily in the treatment of colorectal cancer.

Metastatic colorectal cancer: used in combination regimens to extend survival. Locally advanced colorectal cancer: employed as part of neoadjuvant therapy to reduce tumor burden. Colorectal cancer refractory to other agents: provides an alternative mechanism of action.

Irinotecan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Diarrhea: may be severe and require supportive care. - Nausea and vomiting: often managed with antiemetics. - Fatigue: generalized tiredness during treatment. - Alopecia: temporary hair loss. - Mild liver enzyme elevation.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils requiring urgent medical attention. - Severe colitis or ileitis: life‑threatening intestinal inflammation. - Hepatic toxicity: marked elevation of bilirubin or transaminases. - Anaphylactic reactions: acute hypersensitivity requiring immediate intervention. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for toxicity.

Dose adjustment: renal or hepatic impairment may require modification. Monitoring: regular complete blood counts and liver function tests are recommended. Hydration: maintain adequate fluids to reduce risk of severe diarrhea. Drug interactions: avoid concurrent strong CYP3A4 inhibitors without supervision. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Irinotecan can interact with several medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase SN‑38 exposure and toxicity. - UGT1A1*28 homozygosity: heightened risk of severe neutropenia and diarrhea. - Concurrent myelosuppressive agents: additive bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Antiemetics such as ondansetron: may affect metabolism of irinotecan. - Warfarin: potential increase in bleeding risk. - Proton‑pump inhibitors: may alter gastric pH and affect drug absorption.